Table 4.
More detailed follow up findings (SUVmax, IgG4 levels, sites of involvement, and treatment regimen) of patients with repeated FDG PET/CT
| Initial FDG PET/CT SUVmax (organ) | SUVR | Other sites involved | Follow-up SUV Max |
SUVR | Duration from initial scan (months) | IgG4 at diagnosis (mg/dL) | Latest subsequent IgG4 levels (mg/dL) | Initial prednisolone dose or any other medication | Current prednisolone dose or any other medication |
|---|---|---|---|---|---|---|---|---|---|
| 5.1 (coronary vessels) | 1.59 | Lymph nodes kidneys |
4.2 | 1.2 | 48 | 269 | 340 (4 years) |
50 mg OM | 7.5 mg OM |
| 5.2 (coronary vessels) |
1.73 | Lymph nodes right iliac artery pericardium |
* | * | 38 | 22 | 159 (3 years) |
30 mg BD rituximab mycofenolate mofeteil 1 g BD |
5 mg OM |
| 8.7 (lymph nodes) |
2.49 | Lacrimal gland salivary gland pericardium Pancreas |
* | * | 11 | 51 | 193 (1 year) |
80 mg OM | 5 mg OM Mycofenolate mofeteil 1 g BD |
| 8.4 (periaortic mass) |
2.71 | Lacrimal gland lymph nodes |
* | * | 23 | 149 | 158 (1 year) |
30 mg OM methotrexate 20 mg once/week |
3 mg OM Methotrexate 15 mg once/week |
* denotes background levels of activity on FDG PET/CT
SUVR – SUVmax to liver SUVmax ratio